



1 May 2015

ASX ANNOUNCEMENT

Trading Update: Nine months ended 31 March 2015

Medical Developments International Limited (“MVP”) advise sales for the nine months ended 31 March, 2015 are \$8.3m, up 24% on the previous year. Sales of Pentrox are 35% higher and sales of Respiratory Devices are 53% higher than for the same period last year.

EBITDA is \$1.6m, up 300% for the same period last year and the company expects to have repaid all its banking facilities by the end of FY15.

MVP hope to make further announcements about approvals in Europe and Licencing deals in the near future.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
0414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox[®], a fast acting minor trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.